Breast Cancer Clinical Trial
NBE-002 in Patients With Advanced Solid Tumors
Summary
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Age ≥18 years
Phase 1, DEC and SEC: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma), who have progressive disease, have undergone systemic therapy for advanced disease, and for whom no standard therapy is available
Phase 2, EC1: patients with histologically or cytologically confirmed advanced triple-negative breast cancer, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
Phase 2, EC2: patients with histologically or cytologically confirmed advanced solid tumor (carcinoma or sarcoma) other than TNBC, who have progressive disease, and have undergone no more than three prior lines of systemic therapy for advanced disease
Availability of pretreatment tumor tissue
Phase 1, DEC and SEC: at least one measurable or non-measurable lesion as per RECIST v1.1
Phase 2, EC1 and EC2: at least one measurable lesion as per RECIST v1.1
Phase 1, DEC and SEC: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Phase 2, EC1 and EC2: ECOG performance status of 0 or 1
Adequate function of bone marrow, liver, kidneys, heart; adequate coagulation profile
Both male and female patients must agree to use effective contraceptive methods
Women of child-bearing potential (WCBP) must have a negative serum pregnancy test
Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
Prior treatment with any agent targeting ROR1
Presence of active central nervous system (CNS) metastasis
Persistent toxicities from previous systemic anti-neoplastic treatments of Grade > 1 (or Grade > 2 for neurotoxicity)
Systemic anti-neoplastic therapy within five half-lives or four weeks (six weeks for nitrosourea and mitomycin-C), whichever is shorter, prior to first dose of the study drug
Wide-field radiotherapy within four weeks, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within two weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
Major surgery within four weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
Prior allogeneic bone marrow transplantation
Significant cardiac disease
History of thromboembolic or cerebrovascular events within six months prior to first dose of the study drug
Acute and/or clinically significant bacterial, fungal or viral infection
Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day
Concurrent participation in another investigational clinical trial
Pregnant or breast-feeding females
Other conditions that prevent the patient from giving informed consent or participating in the trial, or that may increase the risk associated with the study participation, or that may interfere with the interpretation of the study results
Prior history of malignancy other than inclusion diagnosis within three years prior to first dose of the study drug
Prior treatment with cumulative lifetime dose of anthracycline
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Nashville Tennessee, 37203, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Contact
Principal Investigator
San Antonio Texas, 78229, United States More Info
Principal Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.